In particular, the median Ang-2 level in NSCLC patients (n = 16) who received platin-based chemotherapy in combination with anti-VEGF factor was significantly higher after the third cycle of chemotherapy when compared with the Ang-2 serum level at admission (median concentration; 4285 pg/mL vs. 2734 pg/mL, Wilcoxon signed rank test, p = 0.044, Figure 5A). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.